Working...
ClinicalTrials.gov
ClinicalTrials.gov Menu

QUILT-3.055: A Study of ALT-803 in Combination With PD-1/PD-L1 Checkpoint Inhibitor in Patients With Advanced Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03228667
Recruitment Status : Recruiting
First Posted : July 25, 2017
Last Update Posted : February 28, 2019
Sponsor:
Information provided by (Responsible Party):
Altor BioScience

Brief Summary:
This is a Phase IIb, single-arm, multicohort, open-label multicenter study of ALT-803 in combination with an FDA-approved PD-1/PD-L1 checkpoint inhibitor in patients with advanced cancers who have progressed following an initial response to treatment with PD-1/PD-L1 checkpoint inhibitor therapy. All patients will receive the combination treatment of PD-1/PD-L1 checkpoint inhibitor plus ALT-803 for up to 16 cycles. Each cycle is six weeks in duration. All patients will receive ALT-803 once every 3 weeks. Patients will also receive the same checkpoint inhibitor that they received during their previous therapy. Radiologic evaluation will occur at the end of each treatment cycle. Treatment will continue for up to 2 years, or until the patient experiences confirmed progressive disease or unacceptable toxicity, withdraws consent, or if the Investigator feels it is no longer in the patient's best interest to continue treatment. Patients will be followed for disease progression, post-therapies, and survival through 24 months past administration of the first dose of study drug.

Condition or disease Intervention/treatment Phase
Non-Small Cell Lung Cancer Small Cell Lung Cancer Urothelial Carcinoma Head and Neck Squamous Cell Carcinoma Merkel Cell Carcinoma Melanoma Renal Cell Carcinoma Gastric Cancer Cervical Cancer Hepatocellular Carcinoma Microsatellite Instability Mismatch Repair Deficiency Colorectal Cancer Drug: ALT-803 + Pembrolizumab Drug: ALT-803 + Nivolumab Drug: ALT-803 + Atezolizumab Drug: ALT-803 + Avelumab Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 611 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: QUILT-3.055: A Phase IIb, Single-Arm, Multicohort, Open-Label Study of ALT-803 in Combination With PD-1/PD-L1 Checkpoint Inhibitor in Patients Who Have Disease Progression Following an Initial Response to Treatment With PD-1/PD-L1 Checkpoint Inhibitor Therapy
Actual Study Start Date : December 11, 2018
Estimated Primary Completion Date : June 2020
Estimated Study Completion Date : August 2020


Arm Intervention/treatment
Cohort 1

Patients with any of the cancers listed below who have progressed on or after single-agent checkpoint inhibitor therapy after experiencing an initial complete response (CR) or partial response (PR) while taking a checkpoint inhibitor.

1a - Non-small cell lung cancer

1b - Small cell lung cancer

1c - Urothelial carcinoma

1d - Head and neck squamous cell carcinoma

1e - Merkel cell carcinoma

1f - Melanoma

1g - Renal cell carcinoma

1h - Gastric cancer

1i - Cervical cancer

1j - Hepatocellular carcinoma

1k - Microsatellite instability-high or mismatch repair deficient solid tumor cancer or colorectal cancer

Drug: ALT-803 + Pembrolizumab
Patients will receive 200 mg pembrolizumab as an intravenous infusion over 30 minutes every three weeks. Patients will receive 15 µg/kg ALT-803 administered by subcutaneous injection every three weeks.

Drug: ALT-803 + Nivolumab
Patients will receive 240 mg nivolumab as an intravenous infusion over 30 minutes every two weeks. Patients will receive 15 µg/kg ALT-803 administered by subcutaneous injection every three weeks.

Drug: ALT-803 + Atezolizumab
Patients will receive 1200 mg atezolizumab as an intravenous infusion over 60 minutes every 3 weeks; if the first infusion is tolerated, subsequent infusions may be given over 30 minutes. Patients will receive 15 µg/kg ALT-803 administered by subcutaneous injection every three weeks.

Drug: ALT-803 + Avelumab
Patients will receive 10 mg/kg avelumab as an intravenous infusion over 60 minutes every 2 weeks. Patients will receive 15 µg/kg ALT-803 administered by subcutaneous injection every three weeks.

Cohort 2
Patients with NSCLC whose tumors have high PD-L1 expression (TPS ≥ 50%) and who relapsed on a PD-1 checkpoint inhibitor after experiencing an initial CR or PR when they received checkpoint inhibitor as a single-agent for first-line treatment.
Drug: ALT-803 + Pembrolizumab
Patients will receive 200 mg pembrolizumab as an intravenous infusion over 30 minutes every three weeks. Patients will receive 15 µg/kg ALT-803 administered by subcutaneous injection every three weeks.

Cohort 3
Patients with NSCLC who had an initial CR or PR but subsequently relapsed on maintenance PD-1 checkpoint inhibitor therapy when they initially received checkpoint inhibitor therapy in combination with chemotherapy as first-line treatment.
Drug: ALT-803 + Pembrolizumab
Patients will receive 200 mg pembrolizumab as an intravenous infusion over 30 minutes every three weeks. Patients will receive 15 µg/kg ALT-803 administered by subcutaneous injection every three weeks.

Experimental: Cohort 4
Patients who are currently receiving PD-1/PD-L1 checkpoint inhibitor therapy and have disease progression after experiencing stable disease (SD) for at least 6 months during their previous treatment with PD-1/PD-L1 checkpoint inhibitor therapy.
Drug: ALT-803 + Pembrolizumab
Patients will receive 200 mg pembrolizumab as an intravenous infusion over 30 minutes every three weeks. Patients will receive 15 µg/kg ALT-803 administered by subcutaneous injection every three weeks.

Drug: ALT-803 + Nivolumab
Patients will receive 240 mg nivolumab as an intravenous infusion over 30 minutes every two weeks. Patients will receive 15 µg/kg ALT-803 administered by subcutaneous injection every three weeks.

Drug: ALT-803 + Atezolizumab
Patients will receive 1200 mg atezolizumab as an intravenous infusion over 60 minutes every 3 weeks; if the first infusion is tolerated, subsequent infusions may be given over 30 minutes. Patients will receive 15 µg/kg ALT-803 administered by subcutaneous injection every three weeks.

Drug: ALT-803 + Avelumab
Patients will receive 10 mg/kg avelumab as an intravenous infusion over 60 minutes every 2 weeks. Patients will receive 15 µg/kg ALT-803 administered by subcutaneous injection every three weeks.




Primary Outcome Measures :
  1. Objective Response Rate [ Time Frame: 24 months ]
    Assess the anti-tumor activity of ALT-803 in combination with a PD-1/PD-L1 checkpoint inhibitor in patients with advanced cancers who have progressed following an initial response to treatment with PD-1/PD-L1 checkpoint inhibitors.


Secondary Outcome Measures :
  1. Disease-specific Survival [ Time Frame: 24 months ]
    Assess time from first treatment to death resulting from cancer.

  2. Overall Survival [ Time Frame: 24 months ]
    Assess time from first treatment to death resulting from any cause.

  3. Time to Response [ Time Frame: 24 months ]
    Assess time to response

  4. Duration of Response [ Time Frame: 24 months ]
    Assess duration of response

  5. Incidence of Adverse Events [ Time Frame: 24 months ]
    Assess incidence of adverse events.

  6. Quality of Life (QOL) [ Time Frame: 24 months ]
    Compare changes in QOL scores from baseline.

  7. Progression-free Survival [ Time Frame: 24 months ]
    Assess amount of time disease does not get worse after first treatment.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

• Voluntary written informed consent and HIPAA authorization and agree to comply with all protocol-specified procedures and follow-up evaluations

  1. Cohort 1 will enroll patients who have disease progression per RECIST v1.1 on or after single-agent checkpoint inhibitor therapy after experiencing an initial response (ie, confirmed CR or PR by RECIST V1.1) while taking checkpoint inhibitor therapy. Patients will be enrolled into distinct cohorts (1a-1k) based on cancer type.

    Patients must have been treated with checkpoint inhibitor therapy after progressing on SoC therapy for their disease, as per FDA indication detailed below:

    • 1a - For metastatic squamous or nonsquamous NSCLC with progression on or after nivolumab, pembrolizumab, or atezolizumab, initial SoC therapy must have been for disease with progression on or after one prior platinum doublet-based chemotherapy regimen. Patients with EGFR or ALK genomic tumor aberrations should have had disease progression on FDA-approved targeted therapy for these aberrations prior to receiving checkpoint inhibitor.
    • 1b - For metastatic SCLC with disease progression on or after nivolumab monotherapy, initial SoC treatment must have been for disease with progression after platinum-based chemotherapy and at least one other line of therapy prior to receiving checkpoint.
    • 1c - Locally advanced or metastatic urothelial carcinoma as follows:
    • For patients with progression on or after nivolumab monotherapy, initial SoC must have been for disease with progression on or after platinum-based chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-based chemotherapy.
    • For patients with disease progression on or after pembrolizumab, initial SoC therapy may have been for locally advanced or metastatic urothelial carcinoma ineligible for cisplatin-containing chemotherapy with PD-L1 tumor expression of CPS ≥ 10 (as determined by FDA-approved test), OR metastatic urothelial carcinoma not eligible for any platinum-containing chemotherapy regardless of PD-L1 status, OR locally advanced or metastatic urothelial carcinoma with progression on or after platinum-based chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-based chemotherapy.
    • For patients with disease progression on or after atezolizumab, initial SoC therapy may have been for locally advanced or metastatic urothelial carcinoma not eligible for cisplatin-based chemotherapy that expresses PD-L1 (PD-L1 stained tumor-infiltrating immune cells [IC] covering ≥ 5% of the tumor area, as determined by an FDA-approved test), OR not eligible for cisplatin-based chemotherapy regardless of PD-L1 status, OR with progression on or after platinum-based chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-based chemotherapy.
    • For patients with disease progression on or after avelumab, initial SoC therapy may have been for locally advanced or metastatic urothelial carcinoma with progression on or after platinum-based chemotherapy or within 12 months of neoadjuvant or adjuvant treatment with platinum-based chemotherapy.
    • 1d - Recurrent or metastatic HNSCC as follows:
    • For patients with disease progression on or after nivolumab monotherapy, initial SoC treatment must have been for disease with progression on or within 6 months of a platinum-based therapy administered in the adjuvant, neoadjuvant, primary (unresectable locally advanced), or metastatic setting.
    • For patients with disease progression on or after pembrolizumab monotherapy, initial SoC treatment must have been for disease with progression on or after platinum-based chemotherapy, or after platinum-based chemotherapy administered as part of induction, concurrent, or adjuvant therapy.
    • 1e - For histologically confirmed metastatic MCC with progression on or after avelumab or pembrolizumab, initial SoC therapy must have been for disease with progression on or after chemotherapy administered for distant metastatic disease; OR recurrent locally advanced or metastatic MCC not treated with prior systemic therapy for advanced disease.
    • 1f - Metastatic melanoma as follows:
    • For patients with disease progression on or after nivolumab administered as a single agent, in combination with ipilimumab, or in the adjuvant setting, initial SoC treatment must have been for unresectable or metastatic melanoma with progression on or after ipilimumab treatment, and if BRAF V600 mutation positive, a BRAF inhibitor; OR BRAF V600 wild-type unresectable or metastatic melanoma previously untreated in the metastatic setting; OR previously untreated, unresectable, or metastatic melanoma not previously treated with anti-CTLA4 antibody; OR completely resected melanoma with lymph node involvement, or stage IIIB/C or stage IV metastatic disease.
    • For patients with disease progression on or after pembrolizumab therapy, initial SoC treatment must have been for unresectable or metastatic melanoma with no prior ipilimumab, and no more than 1 prior systemic treatment for metastatic disease. Patients with BRAF V600E mutation-positive melanoma were not required to have received prior BRAF inhibitor therapy; OR unresectable or metastatic melanoma with progression, refractory to ≥ 2 doses of ipilimumab (3 mg/kg or higher) and, if BRAF V600 mutation-positive, a BRAF or MEK inhibitor, and disease progression within 24 weeks following the last dose of ipilimumab.
    • 1g - For advanced RCC with progression on or after nivolumab monotherapy, initial SoC therapy must have been for disease that progressed after 1 or 2 prior anti-angiogenic therapy regimens. For intermediate or poor risk previously untreated advanced RCC, patients must have progressed on or after nivolumab + ipilimumab.
    • 1h - For recurrent locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma with progression on or after pembrolizumab, initial SoC therapy must have been for disease that progressed on or after ≥ 2 prior lines of therapy including fluoropyrimidine- and platinum-containing chemotherapy and, if appropriate, HER2/neu-targeted therapy. Tumors must express PD-L1 (combined positive score [CPS] ≥ 1), as determined by an FDA-approved test.
    • 1i - For recurrent or metastatic cervical cancer with progression on or after pembrolizumab, initial SoC therapy must have been for disease that progressed on or after chemotherapy. Tumors must express PD-L1 (CPS ≥ 1), as determined by an FDA-approved test.
    • 1j - For HCC with progression on or after pembrolizumab, initial SoC treatment must have been for disease that progressed on or after sorafenib or intolerant to sorafenib. Patients must have had measureable disease and Child-Pugh class A liver impairment. For HCC with progression on or after nivolumab, initial SoC treatment must have been for histologically confirmed HCC with progression on sorafenib or intolerant to sorafenib, and Child-Pugh class A.
    • 1k -Unresectable or metastatic MSI-H or dMMR solid tumors as follows:
    • For patients with progression on or after nivolumab administered as a single agent or in combination with ipilimumab, initial SoC therapy must have been for MSI-H or dMMR metastatic CRC with progression on or after treatment with a fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.
    • For patients with progression on or after pembrolizumab, initial SoC therapy must have been for unresectable or metastatic MSI-H or dMMR solid tumors with progression after prior treatment and no satisfactory alternative treatment options; OR unresectable or metastatic MSI-H or dMMR CRC with progression after treatment with a fluoropyrimidine, oxaliplatin, and irinotecan.
  2. For cohort 2, patients with NSCLC whose tumors have high PD-L1 expression (TPS ≥ 50%) and who have disease progression by RECIST v1.1 on a PD-1 checkpoint inhibitor after experiencing an initial confirmed CR or PR by RECIST v1.1 when they received checkpoint inhibitor as a single-agent for first-line treatment.
  3. For cohort 3, patients with NSCLC who had an initial confirmed CR or PR by RECIST v1.1 but subsequently relapsed (ie, disease progression by RECIST v1.1) on maintenance PD-1 checkpoint inhibitor therapy when they initially received checkpoint inhibitor therapy in combination with chemotherapy as first-line treatment.
  4. For cohort 4, patients with NSCLC, HNSCC, RCC, or urothelial carcinoma who are currently receiving PD-1/PD-L1 checkpoint inhibitor therapy and have disease progression after experiencing SD by RECIST v1.1 for at least 6 months during their previous treatment with PD-1/PD-L1 checkpoint inhibitor therapy.

    • Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
    • Measurable disease by CT or MRI, as defined by RECIST v1.1
    • Treatment of at least 3 months and 1 imaging assessment indicative of a confirmed CR or PR (in accordance with RECIST V1.1) with checkpoint inhibitor (no more than 6 weeks of treatment interruption immediately prior to study enrollment).
    • Patients with genomic tumor aberrations should have received prior treatment with an FDA-approved targeted therapy (if available)
    • Current progressive disease, as defined by RECIST v1.1
    • Adequate organ system function within 14 days of baseline:
    • ANC ≥ 750/µL (≥0.75 x 10^9/L)
    • Platelets ≥ 100,000/µL (≥100 x 10^9/L)
    • Hemoglobin > 8 g/dL
    • Total bilirubin < 2.0 x ULN
    • AST < 3.0 x ULN
    • ALT < 3.0 x ULN
    • eGFR > 45 mL/min
    • Men and women, ≥ 18 years of age
    • Female participants / women of childbearing potential (WOCBP) must adhere to using a medically accepted method of birth control up to 28 days prior to screening and agree to continue its use during the study or be surgically sterilized (e.g., hysterectomy or tubal ligation) and males must agree to use barrier methods of birth control while on study. WOCBP must agree to use effective contraception during treatment and for at least 5 months following the last dose of study treatment.
    • Women of child-bearing potential must have a negative serum pregnancy test during Screening and a negative urine pregnancy test within 24 hours prior to first dose of study treatment. Non-childbearing is defined as greater than one year postmenopausal or surgically sterilized.

Exclusion Criteria:

  • Patients with CNS metastases with the following exceptions:
  • Patient untreated CNS metastases with 4 or fewer sites of disease, with no single site larger than 20mm, are eligible if they are asymptomatic and not requiring steroids at any dose. Patients with asymptomatic CNS metastases may be treated with radiosurgery before or during therapy on trial without treatment delays.
  • Patients with treated, symptomatic CNS metastases are eligible if they are neurologically returned to baseline (except for residual signs or symptoms related to the CNS treatment) for at least 2 weeks prior to registration AND either off corticosteroids, or on a stable or decreasing dose of ≤ 10 mg daily prednisone (or equivalent).
  • New York Heart Association (NYHA) Class III or IV heart failure, uncontrollable supraventricular arrhythmias, any history of a ventricular arrhythmia, or other clinical signs of severe cardiac dysfunction
  • Symptomatic congestive heart failure, unstable angina pectoris, or myocardial infarction within 6 months of enrollment
  • Known autoimmune disease requiring active treatment.
  • History of interstitial lung disease and/or immune mediated pneumonitis
  • Known HIV-positive
  • Active systemic infection requiring parenteral antibiotic therapy
  • Positive hepatitis C serology or active hepatitis B infection
  • Any ongoing toxicity from prior anti-cancer treatment that, in the judgement of the investigator, may interfere with study treatment. All toxicities attributed to prior anti-cancer therapy other than alopecia and fatigue must resolve to grade 1 (NCI CTCAE version 4) or baseline prior to enrollment. Eligible patients must not require more than 10 mg/day prednisone (or equivalent dose).
  • Previous malignancies (except non-melanoma skin cancers, in situ bladder cancer, in situ gastric or in situ colon cancers, in situ cervical cancers/dysplasia or breast carcinoma in situ) unless a complete remission was achieved at least 1 year prior to study entry and no additional therapy is required or anticipated to be required during the study period
  • No other illness that in the opinion of the investigator would exclude the subject from participating in the study
  • Patients in which treatment with PD-1/PD-L1 checkpoint inhibitor is contraindicated
  • Patients who have received another investigational agent within the previous 3 months
  • Women who are pregnant or nursing

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03228667


Contacts
Layout table for location contacts
Contact: Amy Rock, PhD 954-443-8600 amyrock@altorbioscience.com
Contact: Liza Hernandez, BS 954-443-8600 lizahernandez@altorbioscience.com

Locations
Layout table for location information
United States, Alaska
Alaska Clinical Research Center Recruiting
Anchorage, Alaska, United States, 99530
Contact: Ashli Meek    907-276-1455    ameek@akmed.com   
Principal Investigator: Musaberk Goksel, MD         
United States, California
Chan Soon-Shiong Institute for Medicine Recruiting
El Segundo, California, United States, 90245
Contact: Clinical Trials Navigator       patients@cssifm.org   
Principal Investigator: Mira Kistler, MD         
Glendale Adventist Medical Center Recruiting
Glendale, California, United States, 91206
Contact: Javier Valeriano    818-409-8009    javier.valeriano@ah.org   
Contact: Kristin Melendrez    818-409-8009    kristin.melendrea@ah.org   
Principal Investigator: Mihran Shirinian, MD         
Desert Hematology Oncology Medical Group, Inc. Recruiting
Rancho Mirage, California, United States, 92270
Contact: Carolyn Arrieta       carolyndho@aol.com   
Principal Investigator: Luke P Dreisbach, MD         
United States, Kentucky
Baptist Health - Lexington Recruiting
Lexington, Kentucky, United States, 40503
Contact: Cortney Grimes    589-260-3196    cortney.grimes@bhsi.com   
Principal Investigator: Firas Badin, MD         
United States, Michigan
Henry Ford Hospital Recruiting
Detroit, Michigan, United States, 48202
Contact: Trevor I Seixas    313-916-0482    tseixas1@hfhs.org   
Principal Investigator: Igor I Rybkin, MD         
United States, Minnesota
University of Minnesota - Masonic Cancer Center Recruiting
Minneapolis, Minnesota, United States, 55455
Contact: Sarah Smith    612-624-5949    pett0127@umn.edu   
Principal Investigator: Manish Patel, MD         
United States, Missouri
Mercy Research Joplin Recruiting
Joplin, Missouri, United States, 64804
Contact: Esmeralda R Carrillo       Esmeralda.Carrillo@mercy.net   
Principal Investigator: Samir M Dalia, MD         
Mercy Clinic Cancer & Hematology - Chub O'Reilly Cancer Center Recruiting
Springfield, Missouri, United States, 65804
Contact: Pearlena C Hamlet       pearlena.hamlet@mercy.net   
Principal Investigator: Mohan Tummala, MD         
United States, New York
Roswell Park Cancer Institute Recruiting
Buffalo, New York, United States, 14263
Contact: Charles Skipper    716-845-4185    charles.skipper@roswellpark.org   
Principal Investigator: Edwin Yau, MD         
United States, Ohio
Cleveland Clinic - Main Site Recruiting
Cleveland, Ohio, United States, 44195
Contact: Makenzie Guy    216-445-8492    guym@ccf.org   
Principal Investigator: Nathan Pennell, MD         
United States, Oklahoma
Mercy Clinic Oklahoma City Recruiting
Oklahoma City, Oklahoma, United States, 73120
Contact: Sheryl R Freeland    405-752-3402    sheryl.freeland@mercy.net   
Principal Investigator: Carla Kurkjian, MD         
United States, South Carolina
Medical University of South Carolina Recruiting
Charleston, South Carolina, United States, 29425
Contact: Eleanor Hardy    843-792-4421    hardyel@musc.edu   
Principal Investigator: John Wrangle, MD, MPH         
St. Francis Cancer Center/Bon Secours St. Francis Health System Recruiting
Greenville, South Carolina, United States, 29607
Contact: Melissa F Beckman       melissa_beckman@bshsi.org   
Principal Investigator: Robert Siegel, MD.         
Spartanburg Medical Center Recruiting
Spartanburg, South Carolina, United States, 29303
Contact: Susan Stanley       sstanley@gibbscc.org   
Principal Investigator: Vikas Dembla, MD         
United States, South Dakota
Sanford Clinical Research Recruiting
Sioux Falls, South Dakota, United States, 57104
Contact: Jane Veerman, RN    605-328-1373    Jane.veerman@sanfordhealth.org   
Contact: Sarah Timm, MA    605-328-1373    sarah.timm@sanfordhealth.org   
Principal Investigator: Christopher Sumey, MD         
United States, Virginia
Bon Secours Richmond Recruiting
Richmond, Virginia, United States, 23114
Contact: Melissa S Godsey    804-893-8611 ext 8048938611    melissa_godsey@bshsi.org   
Principal Investigator: William J Irvin, MD         
Sponsors and Collaborators
Altor BioScience

Layout table for additonal information
Responsible Party: Altor BioScience
ClinicalTrials.gov Identifier: NCT03228667     History of Changes
Other Study ID Numbers: CA-ALT-803-02-17
First Posted: July 25, 2017    Key Record Dates
Last Update Posted: February 28, 2019
Last Verified: February 2019
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Altor BioScience:
Non-Small Cell Lung Cancer (NSCLC)
Small Cell Lung Cancer (SCLC)
Head and Neck Squamous Cell Carcinoma (HNSCC)
Merkel Cell Carcinoma (MCC)
Renal Cell Carcinoma (RCC)
Gastric Cancer
Cervical Cancer
Mismatch Repair Deficient (dMMR) Solid Tumor Cancer
Colorectal Cancer (CRC)
Pembrolizumab
Nivolumab
Immunotherapy
Interleukin-15
PD-1 Checkpoint Inhibitor
ALT-803
Atezolizumab
Avelumab
Urothelial Carcinoma
Melanoma
Hepatocellular Carcinoma (HCC)
Microsatellite Instability-High (MSI-H)
PD-L1 Checkpoint Inhibitor

Additional relevant MeSH terms:
Layout table for MeSH terms
Lung Neoplasms
Carcinoma, Non-Small-Cell Lung
Colorectal Neoplasms
Carcinoma, Squamous Cell
Stomach Neoplasms
Uterine Cervical Neoplasms
Carcinoma, Renal Cell
Small Cell Lung Carcinoma
Carcinoma, Transitional Cell
Squamous Cell Carcinoma of Head and Neck
Carcinoma, Merkel Cell
Brain Neoplasms
Neoplastic Syndromes, Hereditary
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Respiratory Tract Neoplasms
Thoracic Neoplasms
Neoplasms by Site
Lung Diseases
Bronchial Neoplasms
Neuroendocrine Tumors
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Intestinal Neoplasms
Gastrointestinal Neoplasms
Digestive System Neoplasms
Neoplasms, Squamous Cell
Liver Neoplasms